We have located links that may give you full text access.
Rare Variants in Complement Gene in C3 Glomerulopathy and Immunoglobulin-Mediated Membranoproliferative Glomerulonephritis.
BACKGROUND: C3 glomerulopathy and idiopathic immunoglobulin-mediated membranoproliferative glomerulonephritis (Ig-MPGN) are rare complement mediated kidney diseases. Inherited forms of C3 glomerulopathy/Ig-MPGN are rarely described.
METHODS: Three hundred ninety-eight patients with C3 glomerulopathy (n=296) or Ig-MPGN (n=102) from a national registry were screened for 3 complement genes, factor H (CFH), factor I (CFI) and C3. Patients with rare variant (minor allele frequency <0.1%) were included. Epidemiological, clinical and immunological data at diagnosis and kidney outcomes of patients were retrospectively collected.
RESULTS: Fifty-three different rare variants including 30 (57%), 13 (24%) and 10 (19%) CFH, CFI and C3 variants, were identified in 66/398 (17%) patients. Thirty-eight (72%) variants were classified as pathogenic including 20/30 (66%) and 11/13 (84%) variants in CFH and CFI respectively, impairing synthesis of factor H or Factor I regulators. Fifteen on 53 (27%) variants were of unknown significance. At diagnosis, 69% of patients were adult (median age of 31 years). With the exception of biological stigma of thrombotic microangiopathy, which was more frequent in patients with CFI variants (5/14 (36%) vs 1/37 (3%) and 0% in CFH group and C3 group, p<0.001), the clinical and histological features were similar among the three variants groups. The kidney outcome was poor regardless of the age at onset and treatment received. Sixty-five percent (43/66) of patients with rare variant reach end stage kidney disease after a median delay of 41 [19-104] months, compared to 28% (55/195) after a median delay of 34 [12-143] months in the non-variant group. Among 36 patients who received a kidney transplant, two years-recurrence was frequent, occurring in 39% (12/31), without difference between variants groups and led to graft failure in 3 cases.
CONCLUSIONS: In our cohort, 17% of C3 glomerulopathy/Ig-MPGN cases were associated with rare variants in the CFH, CFI, or C3 genes. In the majority of cases, a quantitative deficiency in factor H or factor I is identified. The presence of a rare variant was associated with poor kidney survival.
METHODS: Three hundred ninety-eight patients with C3 glomerulopathy (n=296) or Ig-MPGN (n=102) from a national registry were screened for 3 complement genes, factor H (CFH), factor I (CFI) and C3. Patients with rare variant (minor allele frequency <0.1%) were included. Epidemiological, clinical and immunological data at diagnosis and kidney outcomes of patients were retrospectively collected.
RESULTS: Fifty-three different rare variants including 30 (57%), 13 (24%) and 10 (19%) CFH, CFI and C3 variants, were identified in 66/398 (17%) patients. Thirty-eight (72%) variants were classified as pathogenic including 20/30 (66%) and 11/13 (84%) variants in CFH and CFI respectively, impairing synthesis of factor H or Factor I regulators. Fifteen on 53 (27%) variants were of unknown significance. At diagnosis, 69% of patients were adult (median age of 31 years). With the exception of biological stigma of thrombotic microangiopathy, which was more frequent in patients with CFI variants (5/14 (36%) vs 1/37 (3%) and 0% in CFH group and C3 group, p<0.001), the clinical and histological features were similar among the three variants groups. The kidney outcome was poor regardless of the age at onset and treatment received. Sixty-five percent (43/66) of patients with rare variant reach end stage kidney disease after a median delay of 41 [19-104] months, compared to 28% (55/195) after a median delay of 34 [12-143] months in the non-variant group. Among 36 patients who received a kidney transplant, two years-recurrence was frequent, occurring in 39% (12/31), without difference between variants groups and led to graft failure in 3 cases.
CONCLUSIONS: In our cohort, 17% of C3 glomerulopathy/Ig-MPGN cases were associated with rare variants in the CFH, CFI, or C3 genes. In the majority of cases, a quantitative deficiency in factor H or factor I is identified. The presence of a rare variant was associated with poor kidney survival.
Full text links
Related Resources
Trending Papers
Renin-Angiotensin-Aldosterone System: From History to Practice of a Secular Topic.International Journal of Molecular Sciences 2024 April 5
Albumin: a comprehensive review and practical guideline for clinical use.European Journal of Clinical Pharmacology 2024 April 13
Revascularization Strategy in Myocardial Infarction with Multivessel Disease.Journal of Clinical Medicine 2024 March 27
Clinical practice guidelines on the management of status epilepticus in adults: A systematic review.Epilepsia 2024 April 13
Interstitial Lung Disease: A Review.JAMA 2024 April 23
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app